Horizon Pharma PLC (HZNP) Receives Buy Rating from Jefferies Group LLC
Jefferies Group LLC reissued their buy rating on shares of Horizon Pharma PLC (NASDAQ:HZNP) in a report published on Thursday morning. They currently have a $16.00 target price on the biopharmaceutical company’s stock.
Several other research firms have also recently commented on HZNP. Cantor Fitzgerald reaffirmed a buy rating and issued a $17.00 target price on shares of Horizon Pharma PLC in a research report on Monday, September 11th. Piper Jaffray Companies set a $18.00 target price on shares of Horizon Pharma PLC and gave the stock a buy rating in a research report on Sunday, September 10th. ValuEngine cut shares of Horizon Pharma PLC from a buy rating to a hold rating in a research report on Friday, September 1st. UBS AG set a $16.00 target price on shares of Horizon Pharma PLC and gave the stock a buy rating in a research report on Tuesday, August 8th. Finally, Mizuho reaffirmed a hold rating and issued a $12.00 target price (up from $9.00) on shares of Horizon Pharma PLC in a research report on Monday, August 28th. Five investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $18.00.
Horizon Pharma PLC (HZNP) traded down 3.22% during midday trading on Thursday, reaching $13.54. 2,325,091 shares of the company’s stock traded hands. Horizon Pharma PLC has a 52-week low of $9.45 and a 52-week high of $21.98. The company’s 50-day moving average price is $12.99 and its 200-day moving average price is $12.76. The stock’s market cap is $2.21 billion.
Horizon Pharma PLC (NASDAQ:HZNP) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.12 by $0.29. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The business had revenue of $289.51 million during the quarter, compared to analysts’ expectations of $237.01 million. During the same quarter in the prior year, the company posted $0.56 EPS. The firm’s revenue for the quarter was up 12.5% compared to the same quarter last year. On average, equities analysts predict that Horizon Pharma PLC will post $1.07 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/06/horizon-pharma-plc-hznp-receives-buy-rating-from-jefferies-group-llc.html.
A number of large investors have recently added to or reduced their stakes in HZNP. BlackRock Inc. increased its stake in Horizon Pharma PLC by 68,479.5% during the 1st quarter. BlackRock Inc. now owns 13,261,212 shares of the biopharmaceutical company’s stock valued at $196,001,000 after purchasing an additional 13,241,875 shares in the last quarter. Paulson & CO. Inc. bought a new stake in Horizon Pharma PLC during the 2nd quarter valued at about $58,584,000. Dimensional Fund Advisors LP increased its stake in Horizon Pharma PLC by 119.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 6,265,608 shares of the biopharmaceutical company’s stock valued at $74,373,000 after purchasing an additional 3,409,411 shares in the last quarter. William Blair Investment Management LLC bought a new stake in Horizon Pharma PLC during the 2nd quarter valued at about $23,557,000. Finally, Balyasny Asset Management LLC bought a new stake in Horizon Pharma PLC during the 2nd quarter valued at about $13,958,000. Institutional investors and hedge funds own 82.33% of the company’s stock.
About Horizon Pharma PLC
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Stock Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related stocks with our FREE daily email newsletter.